• Fangbing Ren, Yanhui Ma, Kexin Zhang, Youhong Luo, Ruiyan Pan, Jingwen Zhang, Chengxia Kan, Ningning Hou, Fang Han, and Xiaodong Sun.
• Department of Endocrinology and Metabolism, Affiliated Hospital of Weifang Medical University, Weifang, China.
• Medicine (Baltimore). 2024 May 3; 103 (18): e38023e38023.

AbstractCancer remains a significant challenge in the field of oncology, with the search for novel and effective treatments ongoing. Calycosin (CA), a phytoestrogen derived from traditional Chinese medicine, has garnered attention as a promising candidate. With its high targeting and low toxicity profile, CA has demonstrated medicinal potential across various diseases, including cancers, inflammation, and cardiovascular disease. Studies have revealed that CA possesses inhibitory effects against a diverse array of cancers. The underlying mechanism of action involves a reduction in tumor cell proliferation, induction of tumor cell apoptosis, and suppression of tumor cell migration and invasion. Furthermore, CA has been shown to enhance the efficacy of certain chemotherapeutic drugs, making it a potential component in treating malignant tumors. Given its high efficacy, low toxicity, and multi-targeting characteristics, CA holds considerable promise as a therapeutic agent for cancer treatment. The objective of this review is to present a synthesis of the current understanding of the antitumor mechanism of CA and its research progress.Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.

19 keywords...

hide…